Trump is reportedly trying to lure a German company working on coronavirus vaccine exclusively to the U.S.
No one can fault President Trump for wanting Americans to have access to a coronavirus vaccine in the future, but Germany isn't pleased with the way he's reportedly trying to do it.
Per Reuters, Germany's health ministry confirmed a report from German Newspaper Welt am Sonntag that said Trump has offered funds to lure biopharmaceutical company CureVac, which is working on developing a vaccine for the new virus, from Germany to the United States. Welt am Sonntag quoted an anonymous German official who said Trump would do anything to get a vaccine, "but only for the United States."
A German health ministry official, meanwhile, said Berlin wants to make sure vaccines and other substances that could be used to fight off the coronavirus are developed in Germany and Europe, as well. Above all, the hope is to avoid exclusivity.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"The exclusive sale of a possible vaccine to the USA must be prevented by all means," tweeted Karl Lauterbach, a professor of health economics epidemiology and German lawmaker, in response to the report. "Capitalism has limits."
There was no immediate comment from the U.S. embassy in Berlin, and CureVac declined to comment, but the company's CEO Daniel Menichella met with Trump, Vice Presidnet Mike Pence, and other members of the White House Coronavirus Task Force earlier this month.
CureVac is narrowing its field of vaccine candidates, and hopes to begin testing in June or July. Read more at Reuters.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Bridget Riley: Learning to See – an ‘invigorating and magical ensemble’The Week Recommends The English artist’s striking paintings turn ‘concentration into reverie’
-
‘Stakeknife’: MI5’s man inside the IRAThe Explainer Freddie Scappaticci, implicated in 14 murders and 15 abductions during the Troubles, ‘probably cost more lives than he saved’, investigation claims
-
The UK’s best Christmas pantosThe Week Recommends Dive into the festive cheer, even into the new year, with some traditional favourites and modern twists
-
Phish food for thought: Ben & Jerry’s political turmoilIn the Spotlight War of words over brand activism threatens to ‘overshadow’ the big ice cream deal
-
What a rising gold price says about the global economyThe Explainer Institutions, central banks and speculators drive record surge amid ‘loss of trust’ in bond markets and US dollar
-
US mints final penny after 232-year runSpeed Read Production of the one-cent coin has ended
-
Argentinian beef is at the center of American farmers’ woesThe Explainer ‘It feels like a slap in the face to rural America,’ said one farmer
-
Will latest Russian sanctions finally break Putin’s resolve?Today's Big Question New restrictions have been described as a ‘punch to the gut of Moscow’s war economy’
-
Warner Bros. explores sale amid Paramount bidsSpeed Read The media giant, home to HBO and DC Studios, has received interest from multiple buying parties
-
China’s rare earth controlsThe Explainer Beijing has shocked Washington with export restrictions on minerals used in most electronics
-
Gold tops $4K per ounce, signaling financial uneaseSpeed Read Investors are worried about President Donald Trump’s trade war
